Have a feature idea you'd love to see implemented?
Let us know!
OVID Ovid Therapeutics Inc
Price (delayed)
$1.21
Market cap
$85.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.43
Enterprise value
$70.61M
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these
Highlights
The gross profit has soared by 186% YoY and by 20% from the previous quarter
OVID's revenue has surged by 186% year-on-year and by 20% since the previous quarter
OVID's equity is down by 20% YoY but it is up by 14% from the previous quarter
OVID's quick ratio is down by 46% QoQ and by 42% YoY
Key stats
What are the main financial stats of OVID
Market
Valuations
Earnings
Shares outstanding
70.97M
Market cap
$85.88M
Enterprise value
$70.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.97
Price to sales (P/S)
151.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
124.42
Revenue
$567,535
EBIT
-$29.75M
EBITDA
-$28.12M
Free cash flow
-$52.98M
Per share
Balance sheet
Liquidity
EPS
-$0.43
Free cash flow per share
-$0.75
Book value per share
$1.25
Revenue per share
$0.01
TBVPS
$1.67
Total assets
$118.09M
Total liabilities
$29.19M
Debt
$16.36M
Equity
$88.9M
Working capital
$66.77M
Debt to equity
0.18
Current ratio
5.73
Quick ratio
5.59
Net debt/EBITDA
0.54
Margins
Efficiency
Dividend
EBITDA margin
-4,955%
Gross margin
100%
Net margin
-5,241.5%
Operating margin
-12,008.3%
Return on assets
-22.9%
Return on equity
-33.4%
Return on invested capital
-26.6%
Return on capital employed
-28.6%
Return on sales
-5,241.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OVID stock price
How has the Ovid Therapeutics stock price performed over time
Intraday
0.83%
1 week
3.42%
1 month
6.14%
1 year
-66.48%
YTD
-62.42%
QTD
2.54%
Financial performance
How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$567,535
Gross profit
$567,535
Operating income
-$68.15M
Net income
-$29.75M
Gross margin
100%
Net margin
-5,241.5%
The gross profit has soared by 186% YoY and by 20% from the previous quarter
OVID's revenue has surged by 186% year-on-year and by 20% since the previous quarter
Ovid Therapeutics's net margin has surged by 79% YoY and by 51% QoQ
The operating margin has soared by 56% YoY and by 8% from the previous quarter
Growth
What is Ovid Therapeutics's growth rate over time
Valuation
What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
0.97
P/S
151.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
124.42
The EPS is up by 41% QoQ and by 39% YoY
OVID's price to book (P/B) is 63% less than its 5-year quarterly average of 2.6 and 56% less than its last 4 quarters average of 2.2
OVID's equity is down by 20% YoY but it is up by 14% from the previous quarter
OVID's revenue has surged by 186% year-on-year and by 20% since the previous quarter
OVID's price to sales (P/S) is 70% less than its last 4 quarters average of 511.8 and 53% less than its 5-year quarterly average of 324.1
Efficiency
How efficient is Ovid Therapeutics business performance
The ROS has soared by 79% YoY and by 51% QoQ
OVID's ROIC is up by 46% YoY and by 44% QoQ
The return on assets has increased by 39% since the previous quarter and by 30% year-on-year
Ovid Therapeutics's ROE has increased by 38% from the previous quarter and by 14% YoY
Dividends
What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OVID.
Financial health
How did Ovid Therapeutics financials performed over time
OVID's quick ratio is down by 46% QoQ and by 42% YoY
The company's current ratio fell by 45% QoQ and by 43% YoY
Ovid Therapeutics's debt is 82% lower than its equity
Ovid Therapeutics's debt to equity has plunged by 69% from the previous quarter but it has increased by 20% YoY
Ovid Therapeutics's debt has shrunk by 64% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.